These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27751709)

  • 21. Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of the contributions of specific plants.
    Chen M; May BH; Zhou IW; Sze DM; Xue CC; Zhang AL
    Crit Rev Oncol Hematol; 2016 Sep; 105():18-34. PubMed ID: 27497028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):575-583. PubMed ID: 37460439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis.
    Lee YM; Lang D; Lockwood C
    JBI Libr Syst Rev; 2012; 10(40):2593-2657. PubMed ID: 27820557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
    Bokemeyer C; Gascón P; Aapro M; Ludwig H; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; Abraham I; MacDonald K
    Support Care Cancer; 2017 Jun; 25(6):1819-1828. PubMed ID: 28111718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
    Wang L; Chen YZ; Shi D; Shi XY; Zou Z; Zhao JH
    Drugs R D; 2011 Dec; 11(4):317-26. PubMed ID: 22133387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
    Miyagi T; Tsuji D; Kawasakai Y; Ishikawa H; Tanaka R; Nakao M; Nakagaki S; Hayashi T; Ayuhara H; Harada T; Tamaki S; Maeda A; Ohashi Y; Arakawa Y; Fujita Y; Yamamoto K; Miyamoto Y; Yano T; Itoh K
    Eur J Clin Pharmacol; 2023 Mar; 79(3):407-414. PubMed ID: 36645467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.
    Chao C; Page JH; Yang SJ; Rodriguez R; Huynh J; Chia VM
    Ann Oncol; 2014 Sep; 25(9):1821-1829. PubMed ID: 24915871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis.
    Tegegne BS; Mengesha MM; Teferra AA; Awoke MA; Habtewold TD
    Syst Rev; 2018 Oct; 7(1):161. PubMed ID: 30322409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
    Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
    Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.
    Schwenkglenks M; Pettengell R; Jackisch C; Paridaens R; Constenla M; Bosly A; Szucs TD; Leonard R
    Support Care Cancer; 2011 Apr; 19(4):483-90. PubMed ID: 20306092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes mellitus carries a risk of gastric cancer: a meta-analysis.
    Shimoyama S
    World J Gastroenterol; 2013 Oct; 19(40):6902-10. PubMed ID: 24187468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
    Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis.
    Zhou JG; Tian X; Cheng L; Zhou Q; Liu Y; Zhang Y; Bai YJ; Ma H
    Medicine (Baltimore); 2015 Oct; 94(40):e1719. PubMed ID: 26448029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
    Schwenkglenks M; Pettengell R; Szucs TD; Culakova E; Lyman GH
    J Hematol Oncol; 2010 Aug; 3():27. PubMed ID: 20723212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.